Department of Oncology, Georgetown University Medical Center and Cancer Prevention and Control Program, Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC, USA.
Department of Oncology, Georgetown University Medical Center and Cancer Prevention and Control Program, Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC, USA; Towson University, Maryland, USA.
Breast. 2022 Feb;61:43-57. doi: 10.1016/j.breast.2021.12.003. Epub 2021 Dec 6.
The increasing attention on personalized breast cancer care has resulted in an explosion of new interactive, tailored, web-based clinical decision tools for guiding treatment decisions in clinical practice. The goal of this study was to review, compare, and discuss the clinical implications of current tools, and highlight future directions for tools aiming to improve personalized breast cancer care. We searched PubMed, Embase, PsychInfo, Cochrane Database of Systematic Reviews, Web of Science, and Scopus to identify web-based decision tools addressing breast cancer treatment decisions. There was a total of 17 articles associated with 21 unique tools supporting decisions related to surgery, radiation therapy, hormonal therapy, bisphosphonates, HER2-targeted therapy, and chemotherapy. The quality of the tools was assessed using the International Patient Decision Aid Standard instrument. Overall, the tools considered clinical (e.g., age) and tumor characteristics (e.g., grade) to provide personalized outcomes (e.g., survival) associated with various treatment options. Fewer tools provided the adverse effects of the selected treatment. Only one tool was field-tested with patients, and none were tested with healthcare providers. Future studies need to assess the feasibility, usability, acceptability, as well as the effects of personalized web-based decision tools on communication and decision making from the patient and clinician perspectives.
越来越多的人关注个性化乳腺癌护理,导致大量新的交互式、定制化、基于网络的临床决策工具应运而生,旨在为临床实践中的治疗决策提供指导。本研究旨在对当前工具的临床意义进行回顾、比较和讨论,并强调旨在改善个性化乳腺癌护理的工具的未来方向。我们检索了 PubMed、Embase、PsychInfo、Cochrane 系统评价数据库、Web of Science 和 Scopus,以确定针对乳腺癌治疗决策的基于网络的决策工具。共有 17 篇文章与 21 个独特的工具相关,这些工具支持与手术、放射治疗、激素治疗、双膦酸盐、HER2 靶向治疗和化疗相关的决策。使用国际患者决策辅助工具标准仪器评估工具的质量。总体而言,这些工具考虑了临床因素(如年龄)和肿瘤特征(如分级),以提供与各种治疗选择相关的个性化结局(如生存)。较少的工具提供了所选治疗的不良反应。只有一个工具在患者中进行了现场测试,没有一个工具在医疗保健提供者中进行了测试。未来的研究需要评估基于网络的个性化决策工具从患者和临床医生的角度出发,在沟通和决策方面的可行性、可用性、可接受性以及对其的影响。